For decades, cardiovascular risk assessment has often been reduced to a familiar panel of numbers: total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides.
These remain important. In fact, current European and American guidance continues to regard LDL cholesterol and other apolipoprotein B containing lipoproteins as central, causal drivers of atherosclerotic cardiovascular disease. (Escardio)
But cardiovascular disease is not caused by a single abnormal blood test.
A person can have an apparently reassuring cholesterol result and still carry substantial cardiovascular risk because of elevated lipoprotein(a), hypertension, impaired glucose metabolism, kidney disease, genetics or a strong family history. Conversely, an elevated cholesterol measurement does not automatically mean that an individual has the same absolute cardiovascular risk as someone else with the same result.
The modern approach is therefore moving towards integrated cardiovascular risk assessment.
Rather than asking simply, “What is my cholesterol?”, the more useful question is:
“What is my overall probability of developing cardiovascular disease, and which modifiable factors can we address early?”
The 2026 American Heart Association/American College of Cardiology dyslipidaemia guideline reflects this broader approach, incorporating LDL cholesterol, non-HDL cholesterol, ApoB, lipoprotein(a), triglyceride-rich particles and coronary artery calcium alongside overall cardiovascular risk assessment. (professional.heart.org)
1. ApoB: Counting the Atherogenic Particles
One of the most interesting developments in preventive cardiology is the increasing use of apolipoprotein B, or ApoB.
ApoB is the principal structural protein found on several atherogenic lipoproteins, including LDL particles, very-low-density lipoproteins and other particles capable of contributing to atherosclerosis.
The important distinction is that LDL cholesterol measures the amount of cholesterol carried within LDL particles, whereas ApoB provides information about the number of atherogenic particles.
This distinction can become clinically relevant.
Imagine two people with the same LDL cholesterol concentration. One may have relatively fewer LDL particles carrying more cholesterol per particle, while another may have more particles carrying less cholesterol each.
Their LDL cholesterol can therefore look similar while their ApoB concentrations differ.
This is one reason ApoB can provide additional information in selected patients.
The 2026 AHA/ACC guideline recommends selective ApoB measurement particularly when residual lipoprotein-related risk may not be adequately represented by the standard lipid profile. Examples include people with elevated triglycerides, diabetes or metabolic dysfunction, or those who have achieved a low LDL cholesterol but may still have residual atherogenic particle burden. (professional.heart.org)
When might ApoB be particularly useful?
It can be considered when there is:
- Elevated triglycerides
- Type 2 diabetes or significant metabolic dysfunction
- Metabolic syndrome
- Discordance between LDL cholesterol and other lipid measures
- Premature cardiovascular disease
- A strong family history
- Persistent cardiovascular risk despite apparently satisfactory LDL cholesterol
Importantly, ApoB should not be presented as a replacement for conventional lipid assessment in everybody.
It is an additional tool, and interpretation should occur within the context of the person’s overall cardiovascular risk.
2. Lipoprotein(a): The Genetic Risk Factor Many People Never Know They Have
If ApoB helps us understand the burden of atherogenic particles, lipoprotein(a), or Lp(a), adds another important dimension.
Lp(a) is a cholesterol-rich lipoprotein particle containing apolipoprotein B and an additional protein called apolipoprotein(a).
Unlike many lifestyle-sensitive cardiovascular risk factors, Lp(a) is largely genetically determined.
This makes it particularly interesting in preventive medicine.
A person can eat well, exercise regularly, maintain a healthy weight and have an otherwise favourable lipid profile while still having an inherited elevation in Lp(a).
High Lp(a) is associated with increased risk of atherosclerotic cardiovascular disease, including coronary heart disease and ischaemic stroke. It is also associated with calcific aortic valve disease. (ESC 365)
Why is Lp(a) so important?
Because it can explain part of the cardiovascular risk that otherwise appears unexplained.
For example, consider someone who:
- does not smoke
- exercises regularly
- has a healthy BMI
- has a reasonable LDL cholesterol
- has normal blood pressure
- has no obvious metabolic disease
but whose parent experienced a myocardial infarction at a relatively young age.
An Lp(a) measurement may reveal an inherited risk factor that would otherwise remain invisible.
The 2026 AHA/ACC dyslipidaemia guideline recommends measuring Lp(a) at least once in a lifetime to identify people with elevated inherited cardiovascular risk. It identifies levels of ≥125 nmol/L (50 mg/dL) as a risk-enhancing level, although interpretation depends on the measurement system and clinical context. (professional.heart.org)
Lp(a) concentration is relatively stable throughout life, which is one reason a single measurement can be useful.
But there is an important caveat
An elevated Lp(a) does not mean that a person is destined to develop heart disease.
At present, clinical management largely focuses on aggressively addressing the modifiable cardiovascular risk factors that we can treat, particularly LDL cholesterol and blood pressure.
Targeted Lp(a)-lowering therapies are an active area of research, but Lp(a) is not currently managed in the same way as LDL cholesterol. (ESC 365)
This is a useful example of the difference between risk prediction and disease prediction.
A biomarker can tell us that risk is higher without telling us precisely what will happen to an individual.
3. Blood Pressure: The Silent Cardiovascular Risk Factor
Cholesterol receives enormous attention, but blood pressure deserves equal consideration.
Persistent hypertension damages the cardiovascular system over many years.
It increases the risk of:
- myocardial infarction
- stroke
- heart failure
- chronic kidney disease
- atrial fibrillation
- cognitive decline
The relationship is not simply about a single elevated reading.
Blood pressure varies throughout the day and can be affected by stress, caffeine, exercise, pain, illness and the clinical environment.
This is why home blood pressure monitoring and ambulatory blood pressure monitoring can sometimes provide a much better picture than an isolated clinic reading.
The 2025 AHA/ACC hypertension guideline continues to emphasise a target below 130/80 mmHg for most adults, while treatment decisions depend on the individual’s circumstances and overall cardiovascular risk. (American College of Cardiology)
The guideline also emphasises lifestyle measures including healthy dietary patterns, reducing sodium intake, physical activity, weight management and addressing other cardiovascular risk factors. (American College of Cardiology)
Why does this matter in longevity medicine?
Because blood pressure represents something different from cholesterol.
LDL and ApoB contribute to the development of atherosclerotic plaque.
Blood pressure contributes to the mechanical stress placed on the vascular system.
Over decades, these processes can interact.
A person with elevated ApoB and elevated blood pressure may therefore have considerably greater cardiovascular risk than someone with either abnormality alone.
4. Glycaemic Health: Cardiovascular Risk Begins Before Diabetes
Another important shift in preventive medicine is the recognition that cardiovascular risk is closely linked to metabolic health.
Type 2 diabetes is a major cardiovascular risk factor, but metabolic deterioration generally develops over time.
The progression can involve:
insulin resistance → impaired glucose regulation → prediabetes → type 2 diabetes
However, cardiovascular risk does not suddenly appear on the day someone crosses a diagnostic threshold for diabetes.
Blood glucose, HbA1c, triglycerides, blood pressure, waist circumference, body composition and other metabolic measures can provide a broader picture.
The 2026 AHA/ACC/ADA/ASN cardiovascular-kidney-metabolic guideline explicitly integrates cardiovascular, metabolic and kidney health, recognising that obesity, prediabetes, diabetes, hypertension, abnormal lipids and chronic kidney disease frequently interact rather than occurring as isolated problems. (professional.heart.org)
This is particularly important because metabolic health is highly modifiable.
Lifestyle remains powerful
Regular physical activity can improve insulin sensitivity.
Resistance training can increase or preserve muscle mass.
Aerobic exercise improves cardiorespiratory fitness.
Adequate sleep supports metabolic health.
A dietary pattern rich in vegetables, fruit, legumes, whole grains, nuts, fish and minimally processed foods can support cardiometabolic health.
Weight management may be appropriate for people who are overweight or living with obesity.
The goal should not simply be to chase a particular glucose number.
It is to improve the overall metabolic environment in which cardiovascular disease develops.
5. Family History: Your Cardiovascular Story Starts Before You Do
Family history is one of the simplest and most underused pieces of cardiovascular information.
A patient may arrive with an impressive lifestyle history but report that their father had a myocardial infarction at 48 or their mother developed cardiovascular disease unusually early.
That information changes the conversation.
Family history can reflect a combination of:
- inherited genetic susceptibility
- inherited lipid disorders
- blood pressure tendencies
- diabetes risk
- environmental factors
- shared dietary and lifestyle patterns
Some cardiovascular conditions have strong genetic components. Familial hypercholesterolaemia, for example, is an inherited disorder associated with markedly elevated LDL cholesterol and increased premature cardiovascular risk. (CDC Blogs)
What constitutes a concerning family history?
Clinicians should pay particular attention to premature cardiovascular disease in first-degree relatives.
The exact age thresholds used to define premature disease vary between guidelines and risk tools, but cardiovascular events occurring unusually early in a parent or sibling should prompt a more careful assessment.
This is where genetics can become useful.
Genetic testing is not necessary for everyone.
But when the clinical history suggests an inherited disorder, such as familial hypercholesterolaemia, genetic assessment can sometimes help establish the diagnosis and facilitate appropriate family screening.
6. Genetics: Risk Is Not Destiny
Genetics has become one of the most exciting areas of preventive medicine.
Polygenic risk scores attempt to combine the effects of many genetic variants to estimate an individual’s inherited susceptibility to a particular disease.
However, genetics should be interpreted carefully.
A genetic predisposition does not mean that disease is inevitable.
Conversely, a favourable genetic profile does not eliminate conventional risk factors.
Someone with genetic susceptibility may substantially reduce their absolute risk through appropriate management of blood pressure, lipids, smoking, exercise, nutrition and metabolic health.
This leads to an important principle:
Genetics can identify vulnerability. It does not determine destiny.
The clinical value of genetic testing depends on the particular test, the condition being assessed, the quality of the evidence behind the test and whether the result would actually change management.
This is particularly important in private and longevity medicine, where commercial genetic testing can sometimes move faster than the evidence supporting its clinical interpretation.
7. Beyond the Blood Test: Coronary Artery Calcium
For selected individuals, cardiovascular risk assessment can extend beyond blood tests.
Coronary artery calcium, or CAC, scoring uses CT imaging to detect calcified plaque in the coronary arteries.
A CAC score can help refine cardiovascular risk when the decision about preventive treatment is uncertain.
The 2026 AHA/ACC dyslipidaemia guideline has expanded the role of CAC scoring in selected adults, including its use to help reclassify risk and inform lipid-lowering decisions. (professional.heart.org)
A CAC score of zero can be reassuring in appropriately selected individuals, although it does not mean that cardiovascular risk is literally zero and does not eliminate all indications for treatment.
Similarly, the presence of coronary calcium provides evidence that atherosclerotic plaque has developed.
This illustrates an important distinction:
Risk factors tell us about the probability of disease.
Imaging can sometimes tell us whether disease is already developing.
8. The Cardiovascular Risk Puzzle
The most useful way to think about cardiovascular prevention is therefore not as a collection of isolated tests.
It is a puzzle.
The lipid component
LDL cholesterol
The established therapeutic target and major causal driver of atherosclerosis.
ApoB
Provides information about the number of atherogenic particles and can be particularly informative when conventional lipid measures may underestimate residual risk.
Lp(a)
A largely genetically determined risk-enhancing factor that is worth measuring at least once in many adults.
The haemodynamic component
Blood pressure
Reflects the chronic pressure load on the cardiovascular system.
The metabolic component
HbA1c and glucose
Help assess glycaemic health.
Triglycerides and metabolic markers
Can provide additional information about cardiometabolic risk.
The inherited component
Family history
Provides information that cannot be obtained from a routine blood test.
Genetics
Can identify selected inherited disorders and, in some circumstances, contribute additional risk information.
The disease component
Coronary artery calcium
Can provide evidence of subclinical coronary atherosclerosis in selected individuals.
9. What Should a Modern Cardiovascular Assessment Look Like?
A sophisticated cardiovascular assessment does notmean ordering every possible biomarker.
It means choosing investigations that answer meaningful clinical questions.
A sensible assessment may begin with:
History
- Smoking
- Family history
- Previous cardiovascular disease
- Diabetes
- Kidney disease
- Pregnancy-related cardiovascular risk factors
- Physical activity
- Diet
- Sleep
- Alcohol intake
- Medication history
Basic measurements
- Blood pressure
- Weight
- BMI
- Waist circumference where appropriate
Standard laboratory assessment
- Total cholesterol
- LDL cholesterol
- HDL cholesterol
- Triglycerides
- HbA1c or glucose
- Renal function
Additional assessment when clinically appropriate
- ApoB
- Lp(a)
- Non-HDL cholesterol
- Additional metabolic assessment
- Genetic testing for suspected inherited disorders
- Coronary artery calcium scoring in selected patients
The key is risk stratification rather than indiscriminate testing.
10. The Longevity Perspective
Perhaps the most important development is that cardiovascular prevention is increasingly being viewed as a lifelong process rather than a response to disease.
Atherosclerosis develops over years.
Hypertension can remain silent for decades.
Metabolic dysfunction may precede diabetes.
Inherited Lp(a) elevation can exist from birth.
Family history can identify susceptibility long before symptoms appear.
This means that the most valuable cardiovascular intervention may occur before the first chest pain, before the first abnormal ECG and before the first cardiovascular event.
The 2026 cardiovascular-kidney-metabolic guideline reinforces this interconnected model, recognising that cardiovascular, metabolic and kidney health influence one another across the life course. (professional.heart.org)
The emerging philosophy is therefore simple:
Do not wait for cardiovascular disease to declare itself. Identify risk early, understand the individual’s biology, and intervene on the factors that can be changed.
But there is an equally important second principle:
More testing is not automatically better medicine.
The goal of preventive medicine is not to generate an impressive laboratory report.
It is to identify meaningful risk, explain it clearly, avoid unnecessary testing and treatment, and use interventions with evidence of improving outcomes.
That is where cardiovascular medicine and responsible longevity medicine increasingly meet.
The Bottom Line
Cholesterol still matters. A great deal.
But cardiovascular risk is considerably more complex than a single LDL cholesterol measurement.
A modern assessment considers:
ApoB to understand atherogenic particle burden.
Lipoprotein(a) to identify an important inherited risk factor.
Blood pressure to assess chronic vascular stress.
Glycaemic and metabolic health to identify cardiometabolic risk before overt disease develops.
Family history and genetics to identify inherited susceptibility.
And, in selected patients, coronary artery calciumto look for evidence of established subclinical atherosclerosis.
The future of cardiovascular prevention is therefore unlikely to be one magical blood test.
It is more likely to be a risk mosaic, bringing together conventional clinical medicine, biomarkers, genetics, imaging and lifestyle information to create a more individualised picture of cardiovascular health.
And perhaps that is the real cardiovascular “holy grail”: not predicting the future perfectly, but identifying modifiable risk early enough to change it.
Selected references
- American Heart Association/American College of Cardiology. 2026 Guideline on the Management of Dyslipidemia.(professional.heart.org)
- American Heart Association/American College of Cardiology. 2026 Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome.(professional.heart.org)
- American Heart Association/American College of Cardiology. 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. (American College of Cardiology)
- European Society of Cardiology/European Atherosclerosis Society. 2025 Focused Update of the ESC/EAS Guidelines for the Management of Dyslipidaemias. (Escardio)
- European Society of Cardiology. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. (Escardio)
- American Heart Association. 2026 Dyslipidemia Guideline: Top Things to Know.(professional.heart.org)
